Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Targeted Search
Clinical Trials Search Results
Query: "TILT[LastUpdatePostDate]SEARCH[Study]AREA[SponsorSearch]Kiniksa Pharmaceuticals"
Count: 12
Selected: 0
| NCT ID | Title |
|---|
| NCT05198310 | Study to Assess the Safety, Pharmacokinetics, and Efficacy of KPL-404 in Participants With Rheumatoid Arthritis With Inadequate Response or Intolerance to at Least One Biologic Disease-modifying Anti-rheumatic Drug or a Janus Kinase Inhibitor | ||
| NCT03816891 | Study to Assess the Efficacy, Safety, and Tolerability of Vixarelimab in Reducing Pruritus in Prurigo Nodularis | ||
| NCT04447469 | Study of Mavrilimumab (KPL-301) in Participants Hospitalized With Severe Corona Virus Disease 2019 (COVID-19) Pneumonia and Hyper-inflammation | ||
| NCT03858634 | A Study to Assess the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Chronic Pruritic Diseases | ||
| NCT03827018 | KPL-301 for Subjects With Giant Cell Arteritis | ||
| NCT04497662 | Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of KPL-404 in Healthy Subjects | ||
| NCT03737110 | Study to Assess the Efficacy and Safety of Rilonacept Treatment in Participants With Recurrent Pericarditis | ||
| NCT04687358 | REgiStry Of the NAtural History of recurreNt periCarditis in pEdiatric and Adult Patients | ||
| NCT03980522 | A Pilot Study of KPL-914 in Recurrent Pericarditis | ||
| NCT04463004 | Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation | ||
| NCT04399980 | Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation | ||
| NCT04492514 | Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflation |
